Editas Chief Playing ‘Long Game’ as Gene-Editing Competition Grows
- Mullen says gene-editing company focused on own technology
- ‘The danger is always chasing the next shiny object’
Editas Medicine CEO James Mullen
Source: GlobalNewswireThis article is for subscribers only.
Editas Medicine Inc., whose stock has shed more than half its value this year, is focused on improving its own gene-editing technology even as competition increases from newer science, Chief Executive Officer James Mullen said.
Eight-year-old Editas, based in Cambridge, Massachusetts, is among the first companies pursuing treatments using Crispr, a Nobel-prize winning technology that edits a person’s genes. The company’s current pipeline includes experimental treatments for eye diseases and blood disorders such as sickle-cell disease.